Search

Stephen C. Buczinski

Examiner (ID: 6852)

Most Active Art Unit
2202
Art Unit(s)
3642, 2603, 2507, 2200, 3202, 2103, 2202, 3662
Total Applications
1988
Issued Applications
1721
Pending Applications
62
Abandoned Applications
204

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17946076 [patent_doc_number] => 20220333093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-10-20 [patent_title] => SITE-SPECIFIC CONJUGATION TO ANTIBODY LYSINE RESIDUES WITH SOLID-PHASE IMMOBILIZED MICROBIAL TRANSGLUTAMINASE MTG AND MTG IN SOLUTION [patent_app_type] => utility [patent_app_number] => 17/704960 [patent_app_country] => US [patent_app_date] => 2022-03-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 107 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17704960 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/704960
SITE-SPECIFIC CONJUGATION TO ANTIBODY LYSINE RESIDUES WITH SOLID-PHASE IMMOBILIZED MICROBIAL TRANSGLUTAMINASE MTG AND MTG IN SOLUTION Mar 24, 2022 Abandoned
Array ( [id] => 17836466 [patent_doc_number] => 20220273771 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES [patent_app_type] => utility [patent_app_number] => 17/697646 [patent_app_country] => US [patent_app_date] => 2022-03-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16688 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17697646 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/697646
SYSTEMS, COMPOSITIONS AND METHODS FOR TREATING DIABETES Mar 16, 2022 Abandoned
Array ( [id] => 19186288 [patent_doc_number] => 20240165201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-23 [patent_title] => GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUNE DISORDERS [patent_app_type] => utility [patent_app_number] => 18/281927 [patent_app_country] => US [patent_app_date] => 2022-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10512 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18281927 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/281927
GALECTIN-1 IMMUNOMODULATION AND MYOGENIC IMPROVEMENTS IN MUSCLE DISEASES AND AUTOIMMUNE DISORDERS Mar 14, 2022 Pending
Array ( [id] => 17828459 [patent_doc_number] => 20220265763 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-25 [patent_title] => POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/689631 [patent_app_country] => US [patent_app_date] => 2022-03-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13733 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17689631 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/689631
POLYPEPTIDE-POLYMER CONJUGATES AND METHODS OF USE THEREOF Mar 7, 2022 Abandoned
Array ( [id] => 19201476 [patent_doc_number] => 20240173375 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-30 [patent_title] => CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO [patent_app_type] => utility [patent_app_number] => 18/548845 [patent_app_country] => US [patent_app_date] => 2022-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26441 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18548845 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/548845
CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO Mar 1, 2022 Pending
Array ( [id] => 18003537 [patent_doc_number] => 20220362303 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => STABILIZED COLOSTRUM COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 17/681166 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30398 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17681166 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/681166
STABILIZED COLOSTRUM COMPOSITIONS Feb 24, 2022 Abandoned
Array ( [id] => 19256332 [patent_doc_number] => 12016356 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-25 [patent_title] => Sweet protein from truffle [patent_app_type] => utility [patent_app_number] => 17/680818 [patent_app_country] => US [patent_app_date] => 2022-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 27431 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17680818 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/680818
Sweet protein from truffle Feb 24, 2022 Issued
Array ( [id] => 17837724 [patent_doc_number] => 20220275029 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-01 [patent_title] => COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY [patent_app_type] => utility [patent_app_number] => 17/673603 [patent_app_country] => US [patent_app_date] => 2022-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38801 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17673603 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/673603
COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY Feb 15, 2022 Abandoned
Array ( [id] => 18405803 [patent_doc_number] => 20230167154 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-01 [patent_title] => MELANOCORTIN 1 RECEPTOR LIGANDS AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 17/582368 [patent_app_country] => US [patent_app_date] => 2022-01-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38037 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17582368 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/582368
Melanocortin 1 receptor ligands and methods of use Jan 23, 2022 Issued
Array ( [id] => 17563156 [patent_doc_number] => 20220127305 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-28 [patent_title] => MELANOCORTIN RECEPTOR LIGANDS [patent_app_type] => utility [patent_app_number] => 17/572115 [patent_app_country] => US [patent_app_date] => 2022-01-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15788 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -218 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17572115 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/572115
MELANOCORTIN RECEPTOR LIGANDS Jan 9, 2022 Abandoned
Array ( [id] => 19164770 [patent_doc_number] => 11980652 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-05-14 [patent_title] => Compositions and methods for subcutaneous administration of cancer immunotherapy [patent_app_type] => utility [patent_app_number] => 17/568251 [patent_app_country] => US [patent_app_date] => 2022-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 18 [patent_no_of_words] => 26294 [patent_no_of_claims] => 58 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17568251 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/568251
Compositions and methods for subcutaneous administration of cancer immunotherapy Jan 3, 2022 Issued
Array ( [id] => 17749664 [patent_doc_number] => 20220227868 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-21 [patent_title] => IMMUNOMODULATORY IL-2 AGENTS IN COMBINATION WITH IMMUNE CHECKPOINT INHIBITORS [patent_app_type] => utility [patent_app_number] => 17/568281 [patent_app_country] => US [patent_app_date] => 2022-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28325 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17568281 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/568281
Immunomodulatory IL-2 agents in combination with immune checkpoint inhibitors Jan 3, 2022 Issued
Array ( [id] => 19050858 [patent_doc_number] => 20240092827 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => PROCESS FOR MANUFACTURING PEPTIDE [patent_app_type] => utility [patent_app_number] => 18/270509 [patent_app_country] => US [patent_app_date] => 2021-12-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12982 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 293 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18270509 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/270509
Process for manufacturing peptide Dec 28, 2021 Issued
Array ( [id] => 17546714 [patent_doc_number] => 20220118055 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-21 [patent_title] => RELEASABLE GLP-1 CONJUGATES [patent_app_type] => utility [patent_app_number] => 17/559692 [patent_app_country] => US [patent_app_date] => 2021-12-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30136 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17559692 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/559692
Releasable GLP-1 conjugates Dec 21, 2021 Issued
Array ( [id] => 17685889 [patent_doc_number] => 20220193181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-23 [patent_title] => S-NITROSOGLUTATHIONE (GSNO) AND GSNO REDUCATASE INHIBITORS FOR USE IN THERAPY [patent_app_type] => utility [patent_app_number] => 17/557628 [patent_app_country] => US [patent_app_date] => 2021-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17557628 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/557628
S-NITROSOGLUTATHIONE (GSNO) AND GSNO REDUCATASE INHIBITORS FOR USE IN THERAPY Dec 20, 2021 Abandoned
Array ( [id] => 18034711 [patent_doc_number] => 20220378926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-01 [patent_title] => PSMA TARGETED CONJUGATE COMPOUNDS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/555958 [patent_app_country] => US [patent_app_date] => 2021-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17555958 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/555958
PSMA targeted conjugate compounds and uses thereof Dec 19, 2021 Issued
Array ( [id] => 19624120 [patent_doc_number] => 12162924 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-12-10 [patent_title] => Method for the design of fibrillar collagen-mimetic peptide self-assemblies [patent_app_type] => utility [patent_app_number] => 17/554650 [patent_app_country] => US [patent_app_date] => 2021-12-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 34 [patent_no_of_words] => 15492 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17554650 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/554650
Method for the design of fibrillar collagen-mimetic peptide self-assemblies Dec 16, 2021 Issued
Array ( [id] => 19273262 [patent_doc_number] => 12023369 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-02 [patent_title] => Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism [patent_app_type] => utility [patent_app_number] => 17/552499 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 3 [patent_no_of_words] => 3764 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 66 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17552499 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/552499
Use of collagen hydrolysate for improving endurance performance and for stimulating lipid catabolism Dec 15, 2021 Issued
Array ( [id] => 18921421 [patent_doc_number] => 20240024425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => PHARMACEUTICAL COMPOSITION OF GLP-1/GLP-2 DUAL AGONISTS [patent_app_type] => utility [patent_app_number] => 18/039857 [patent_app_country] => US [patent_app_date] => 2021-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12617 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18039857 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/039857
PHARMACEUTICAL COMPOSITION OF GLP-1/GLP-2 DUAL AGONISTS Dec 15, 2021 Pending
Array ( [id] => 19497651 [patent_doc_number] => 20240336669 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-10 [patent_title] => NOVEL COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/266571 [patent_app_country] => US [patent_app_date] => 2021-12-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15788 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18266571 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/266571
NOVEL COMPOUNDS Dec 9, 2021 Pending
Menu